NCI strategy for evaluating MCED assays may bypass cancer clinical trials groups

As Trump’s HHS pick, RFK Jr. stands to honor or squander the Kennedy legacy in cancer

President-elect Donald Trump said he would nominate Robert F. Kennedy Jr. to the post of secretary of the Department of Health and Human Services, placing the vaccine skeptic in charge of a vast empire of research, engineering, regulatory, and health care agencies.

NCI renews IU Simon Comprehensive Cancer Center’s designation

NCI renewed the Comprehensive Cancer Center designation to the Indiana University Melvin and Bren Simon Comprehensive Cancer Center, awarding it a five-year, $14.2 million grant.

November 15, 2024

Vol.50 No.43

In Brief

J. Leonard Lichtenfeld joins SpotitEarly as CMO

J. Leonard Lichtenfeld joined SpotitEarly, an Israel-based technology company transforming cancer screening by harnessing the power of artificial intelligence and dogs to detect cancer early, as chief medical officer.

November 15, 2024

Vol.50 No.43

In Brief

Bertagnolli, Goldberg, Gunn, Brundage, and Theiler receive awards at Alliance fall meeting

NIH Director Monica M. Bertagnolli delivered the Charles G. Moertel Lecture at the Fall Group Meeting of the Alliance for Clinical Trials in Oncology. The meeting took place Oct. 30-Nov. 1.

November 15, 2024

Vol.50 No.43

Clinical Roundup

Phase I clinical trial of Keytruda + Lymphir for recurrent solid tumors yields positive preliminary results

Promising preliminary results from an ongoing investigator-initiated phase I clinical trial evaluating the safety and efficacy of a combined regimen of Keytrua (pembrolizumab) and Lymphir (denileukin diftitox-cxdl or E7777) in patients with recurrent solid tumors were announced.

November 15, 2024

Vol.50 No.43

Clinical

NCI’s myeloMATCH will use biomarkers to match patients with myeloid cancer to trials

NCI has launched a second-generation precision medicine clinical trial called Myeloid Malignancies Molecular Analysis for Therapy Choice, or myeloMATCH, a trial focused on acute myeloid leukemia and myelodysplastic syndromes.

October 25, 2024

Vol.50 No.40

By Claire Marie Porter

NCI strategy for evaluating MCED assays may bypass cancer clinical trials groups

YOU MAY BE INTERESTED IN

As Trump’s HHS pick, RFK Jr. stands to honor or squander the Kennedy legacy in cancer

NCI renews IU Simon Comprehensive Cancer Center’s designation

J. Leonard Lichtenfeld joins SpotitEarly as CMO

Bertagnolli, Goldberg, Gunn, Brundage, and Theiler receive awards at Alliance fall meeting

Phase I clinical trial of Keytruda + Lymphir for recurrent solid tumors yields positive preliminary results

NCI’s myeloMATCH will use biomarkers to match patients with myeloid cancer to trials

Renew today!

Subscriber content

Login